CONNECT

Connexin and pannexin channels as drug targets and biomarkers in acute and chronic liver disease

 Coordinatore VRIJE UNIVERSITEIT BRUSSEL 

Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie.

 Nazionalità Coordinatore Belgium [BE]
 Totale costo 1˙473˙928 €
 EC contributo 1˙473˙928 €
 Programma FP7-IDEAS-ERC
Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
 Code Call ERC-2013-StG
 Funding Scheme ERC-SG
 Anno di inizio 2014
 Periodo (anno-mese-giorno) 2014-03-01   -   2019-02-28

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    VRIJE UNIVERSITEIT BRUSSEL

 Organization address address: PLEINLAAN 2
city: BRUSSEL
postcode: 1050

contact info
Titolo: Mr.
Nome: Nik
Cognome: Claesen
Email: send email
Telefono: 3226292210
Fax: 326293640

BE (BRUSSEL) hostInstitution 1˙473˙928.80
2    VRIJE UNIVERSITEIT BRUSSEL

 Organization address address: PLEINLAAN 2
city: BRUSSEL
postcode: 1050

contact info
Titolo: Prof.
Nome: Mathieu Frederick Alexander
Cognome: Vinken
Email: send email
Telefono: 3224774587
Fax: 3224774582

BE (BRUSSEL) hostInstitution 1˙473˙928.80

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

workpackage    liver    consisting    models    animal    vitro    outcome    connect    inflammation    tissue    respectively    death    fibrosis    clinical    gap    channels    hemichannels    panx    connexin    acute    cell    pannexin   

 Obiettivo del progetto (Objective)

'The CONNECT project intends to contribute to the substantiation of the controversial scientific concept stating that hemichannels consisting of connexin32 and connexin43 as well as pannexin1 channels act as pathological pores. This hypothesis will be verified in the specific context of cell death and inflammation, both which are key features of acute liver failure and liver fibrosis. As such, the project is organised in 3 workpackages. In the first workpackage, connexin32, connexin43 and pannexin1 expression and activity will be studied in human and animal diseased liver tissue. The second workpackage is targeted towards the in vitro characterisation of recently generated inhibitors of hemichannels consisting of connexin32 and connexin43 as well as pannexin1 channels, namely Gap24, Gap19 and 10Panx1, respectively. Particular attention will be paid to their target selectivity and potential to reduce cell death and inflammation in liver-based in vitro models. The goal of the third workpackage is to test the in vivo extrapolation of the established in vitro findings. To this end, Gap24, Gap19 and 10Panx1 will be administered to animal models of acute liver failure or liver fibrosis, followed by evaluation of their outcome on cell death, inflammation and clinically relevant read-outs. The CONNECT project is anticipated to significantly impact the connexin and pannexin research area, as it foresees the development and optimisation of new tools and technology to study connexin hemichannels and pannexin channels. The clinical utility of this high risk/high gain project is dual, as it aspires the establishment of novel drug targets and tissue biomarkers for, respectively, the treatment and diagnosis of liver disease. However, given the generic nature of the driving concept, the outcome of the CONNECT project is equally of clinical relevance for a plethora of other pathologies.'

Altri progetti dello stesso programma (FP7-IDEAS-ERC)

BRAINCELL (2010)

Charting the landscape of brain development by large-scale single-cell transcriptomics and phylogenetic lineage reconstruction

Read More  

INCORALS (2012)

Influence of nutrient starvation on corals' susceptibility to bleaching

Read More  

ARCHAELLUM (2013)

Assembly and function of the crenarchaeal flagellum

Read More